Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Share Price

Equities

301126

CNE1000054V3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 14/05/2024 am IST 5-day change 1st Jan Change
10.48 CNY +1.85% Intraday chart for Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd +2.95% -19.57%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 3.29B 456M 38.04B Sales 2023 3.9B 541M 45.11B Capitalization 2.69B 373M 31.09B
Net income 2022 51M 7.06M 589M Net income 2023 34M 4.71M 393M EV / Sales 2022 1.23 x
Net Debt 2022 967M 134M 11.18B Net Debt 2023 1.92B 267M 22.24B EV / Sales 2023 1.18 x
P/E ratio 2022
59.6 x
P/E ratio 2023
76.6 x
Employees 3,461
Yield 2022
0.19%
Yield 2023
0.31%
Free-Float 37.57%
More Fundamentals * Assessed data
Dynamic Chart
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 119.999994 million in funding CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed the share acquisition agreement to acquire 51% stake in Shanxi Simaile Pharmaceutical Chain Co., Ltd. from Yang Jinjiang, Liu Hongming for approximately CNY 330 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire Yinchuan Meihetai Pharmaceutical Chain Co., Ltd. from Xie Huiyang and Xie Xiaolong for approximately CNY 250 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Implements Final Cash Dividend of A Shares for the Year 2022, Payable on June 12, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Final Cash Dividend for 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd cancelled the transaction announced on May 18, 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 300 million in funding CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Proposes Final Cash Dividend for the Year 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Tongjian Pharmacy to Buy 86% Stake in Local Peer For 341 Million Yuan MT
Hunan Tongjian Pharma to Buy 86% of Local TCM Maker For 341 Million Yuan MT
More news
1 day+1.85%
1 week+2.95%
Current month+9.85%
1 month+14.16%
3 months+38.81%
6 months-24.82%
Current year-19.57%
More quotes
1 week
10.11
Extreme 10.11
12.35
1 month
7.59
Extreme 7.59
12.35
Current year
6.61
Extreme 6.61
14.39
1 year
6.61
Extreme 6.61
16.85
3 years
6.61
Extreme 6.61
36.84
5 years
6.61
Extreme 6.61
36.84
10 years
6.61
Extreme 6.61
36.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 16/17/16
Chairman 53 01/02/01
Chairman 59 01/02/01
Members of the board TitleAgeSince
Director/Board Member 51 14/19/14
Director/Board Member 54 10/20/10
Chairman 59 01/02/01
More insiders
Date Price Change Volume
14/24/14 10.48 +1.85% 12,835,470
13/24/13 10.29 -7.05% 15,295,670
10/24/10 11.07 -10.36% 28,471,750
09/24/09 12.35 +20.02% 23,631,870
08/24/08 10.29 +1.08% 5,913,674

End-of-day quote Shenzhen S.E., May 14, 2024

More quotes
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
More about the company
  1. Stock Market
  2. Equities
  3. 301126 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW